Tom Yates
@tomayates.bsky.social
Epidemiology, infection
https://profiles.ucl.ac.uk/37299-tom-yates/about
https://profiles.ucl.ac.uk/37299-tom-yates/about
Surely a big part of this is that TB causes bronchiectasis and NTM thrive in damaged lung?
November 11, 2025 at 7:34 AM
Surely a big part of this is that TB causes bronchiectasis and NTM thrive in damaged lung?
I don't think there are mouse papers in the issue, and mouse models weren't a big focus at the meeting
I'm an epidemiologist by training, but @strangviruslab.bsky.social is a CMV virologist and will have a view
I'm an epidemiologist by training, but @strangviruslab.bsky.social is a CMV virologist and will have a view
November 11, 2025 at 7:32 AM
I don't think there are mouse papers in the issue, and mouse models weren't a big focus at the meeting
I'm an epidemiologist by training, but @strangviruslab.bsky.social is a CMV virologist and will have a view
I'm an epidemiologist by training, but @strangviruslab.bsky.social is a CMV virologist and will have a view
Well done, look forward to reading!
Eliza Nemes suggested badging QFN 0.2 - 0.7 IU/ml as 'indeterminate'
Did QFN using 0.7 threshold perform better?
Perhaps single gene transcripts could be used to resolve indeterminate IGRAs?
Do you have to assay RNA, or could you measure IFN or TNFa directly?
Eliza Nemes suggested badging QFN 0.2 - 0.7 IU/ml as 'indeterminate'
Did QFN using 0.7 threshold perform better?
Perhaps single gene transcripts could be used to resolve indeterminate IGRAs?
Do you have to assay RNA, or could you measure IFN or TNFa directly?
November 7, 2025 at 11:40 AM
Well done, look forward to reading!
Eliza Nemes suggested badging QFN 0.2 - 0.7 IU/ml as 'indeterminate'
Did QFN using 0.7 threshold perform better?
Perhaps single gene transcripts could be used to resolve indeterminate IGRAs?
Do you have to assay RNA, or could you measure IFN or TNFa directly?
Eliza Nemes suggested badging QFN 0.2 - 0.7 IU/ml as 'indeterminate'
Did QFN using 0.7 threshold perform better?
Perhaps single gene transcripts could be used to resolve indeterminate IGRAs?
Do you have to assay RNA, or could you measure IFN or TNFa directly?
I think there are major advantages to the approach
Why expect optimal duration to be a standard number of days, e.g. 3, 5, 7, 10, 14, etc?
With DURATIONS, even if you don't manage to prove non inferiority of e.g. 7 days, top end of the confidence interval can still allow you to shorten treatment
Why expect optimal duration to be a standard number of days, e.g. 3, 5, 7, 10, 14, etc?
With DURATIONS, even if you don't manage to prove non inferiority of e.g. 7 days, top end of the confidence interval can still allow you to shorten treatment
October 19, 2025 at 8:09 AM
I think there are major advantages to the approach
Why expect optimal duration to be a standard number of days, e.g. 3, 5, 7, 10, 14, etc?
With DURATIONS, even if you don't manage to prove non inferiority of e.g. 7 days, top end of the confidence interval can still allow you to shorten treatment
Why expect optimal duration to be a standard number of days, e.g. 3, 5, 7, 10, 14, etc?
With DURATIONS, even if you don't manage to prove non inferiority of e.g. 7 days, top end of the confidence interval can still allow you to shorten treatment
Perhaps, but Matteo published the DURATIONS design paper 7 years ago now
What if the optimal duration turns out to be e.g. 10 days?
What if the optimal duration turns out to be e.g. 10 days?
October 18, 2025 at 2:01 PM
Perhaps, but Matteo published the DURATIONS design paper 7 years ago now
What if the optimal duration turns out to be e.g. 10 days?
What if the optimal duration turns out to be e.g. 10 days?
Why are we still doing duration A vs duration B trials?
October 18, 2025 at 12:32 PM
Why are we still doing duration A vs duration B trials?
Scenario I'm considering has patient on long course of cefazolin for another indication
October 13, 2025 at 6:21 PM
Scenario I'm considering has patient on long course of cefazolin for another indication